Lumosa will participate in the "Biotech Forum" sponsored by Masterlink Securities

Shareholders approved the merger of Lumosa and TPG Bio

Shareholders of Lumosa Therapeutics Co., Ltd. (6535. TPEx) (“Lumosa”) approved its merger with TPG Biologics, Inc. (6521. TPEx) (“TPG”) today. One TPG common share will be exchanged for 0.775 Lumosa common share on a one-time issuance basis; resulting in NTD1.16 billion (approximately USD 38 Million equivalent) capital for the post-merger company. The name of the post-merger company will remain “Lumosa Therapeutics Co., Ltd.”. The completion of the merger is tentatively targeted for October 31, 2018 pending government’s regulatory approval.  Shareholders also approved a fundraising plan through private placement, and authorized the board to proceed with the issuance of common shares under a cap of 75,000,000 shares at a face value of NTD10 per share. The final total amount raised will be determined by the actual issuance price and the number of shares issued.

Lumosa BOD approved TPG Biologics acquisition

(June 8, 2018. Taipei) Lumosa Therapeutics Co., Ltd. (6535. TWO) (“Lumosa”, a TpEx listed company) and TPG Biologics, Inc.(6521. TWO) (“TPG”, listed on the Emerging Stock Market of TPEx) held respective board meeting and approved a merger proposal between Lumosa and TPG.  The merger is expected to integrate R&D resources of the two companies, expand the product portfolio, accelerate new drug development, and enhance overall operation performance. The name of the post-merger company will remain “Lumosa Therapeutics Co., Ltd.”.

Lumosa is public traded on Taipei Exchange (6535.TWO)

Lumosa Therapeutics Co., Ltd., (Lumosa) is listed on the Emerging Stock Board in Taipei Exchange, Symbol 6535, on September 26, 2016. Lumosa is dedicated to new drug development for the treatment of CNS and inflammatory diseases using reSEARCH & DEVELOPMENT model. One of its pipeline, LT1001, is a week-long acting analgesic injection that is awaiting new drug approval from Taiwan FDA. The other, LT3001, is a novel treatment for acute ischemic stroke.